Cargando…

Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?

During the COVID-19 pandemic, concerns raised regarding the use of immunosuppressants in multiple sclerosis, even if current data do not support an increased risk of infection. Although fingolimod can be temporarily suspended during COVID-19, the benefit-risk balance of suspension can be challenging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orrico, Mario, Nozzolillo, Agostino, Gelibter, Stefano, Sangalli, Francesca, Preziosa, Paolo, Filippi, Massimo, Moiola, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045443/ https://www.ncbi.nlm.nih.gov/pubmed/33852086 http://dx.doi.org/10.1007/s00415-021-10556-z

Ejemplares similares

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
por: Preziosa, Paolo, et al.
Publicado: (2020)

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
por: Gelibter, Stefano, et al.
Publicado: (2021)

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
por: S., Guerrieri, et al.
Publicado: (2021)

Intermittent Atrioventricular Block following Fingolimod Initiation
por: Gialafos, E., et al.
Publicado: (2014)

Prognostic factors related to the risk of COVID-19 infection in MS patients
por: Montini, Federico, et al.
Publicado: (2021)

Fingolimod: Type 2 second degree atrioventricular block: case report
Publicado: (2021)

Neurological Consequences of Sphingosine Phosphate Lyase Insufficiency
por: Atreya, Krishan B., et al.
Publicado: (2022)

The effect of the sphingosine‐1‐phosphate analogue FTY720 on atrioventricular nodal tissue
por: Egom, Emmanuel E., et al.
Publicado: (2015)

Energy balance and the sphingosine-1-phosphate/ceramide axis
por: Green, Cara, et al.
Publicado: (2017)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation
por: Ahmed, Naseer, et al.
Publicado: (2017)

Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy
por: Gupta, Preeti, et al.
Publicado: (2021)

The Sphingosine 1-Phosphate Axis: an Emerging Therapeutic Opportunity for Endometriosis
por: Zhang, Fengrui, et al.
Publicado: (2023)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Interaction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer
por: Xu, Guangmeng, et al.
Publicado: (2021)

Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases
por: Kwong, Eric K., et al.
Publicado: (2019)

Fingolimod—A Sphingosine-Like Molecule Inhibits Vesicle Mobility and Secretion in Astrocytes
por: Trkov, Saša, et al.
Publicado: (2012)

Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case–control study
por: Montini, Federico, et al.
Publicado: (2023)

Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression
por: Preziosa, Paolo, et al.
Publicado: (2022)

Insulin Protects Apoptotic Cardiomyocytes from Hypoxia/Reoxygenation Injury through the Sphingosine Kinase/Sphingosine 1-Phosphate Axis
por: Yu, Huan, et al.
Publicado: (2013)

The Role of Sphingolipids and Sphingosine-1-phosphate—Sphingosine-1-phosphate-receptor Signaling in Psoriasis
por: Masuda-Kuroki, Kana, et al.
Publicado: (2023)

Sphingosine‐1‐phosphate/TGF‐β axis drives epithelial mesenchymal transition in asthma‐like disease
por: Riemma, Maria A., et al.
Publicado: (2022)

FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons
por: Takasugi, Nobumasa, et al.
Publicado: (2013)

Sphingosine 1-Phosphate and Atherosclerosis
por: Kurano, Makoto, et al.
Publicado: (2018)

Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis
por: Dai, Lan, et al.
Publicado: (2017)

Sphingosine 1-phosphate axis: a new leader actor in skeletal muscle biology
por: Donati, Chiara, et al.
Publicado: (2013)

Sphingosine kinase/sphingosine 1-phosphate axis: a new player for insulin-like growth factor-1-induced myoblast differentiation
por: Bernacchioni, Caterina, et al.
Publicado: (2012)

Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer
por: Bao, Yonghua, et al.
Publicado: (2017)

Reflex Atrioventricular Block
por: Sutton, Richard
Publicado: (2020)

Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease
por: Ceccom, Johnatan, et al.
Publicado: (2014)

Dihydro-sphingosine 1-phosphate interacts with carrier proteins in a manner distinct from that of sphingosine 1-phosphate
por: Mishima, Yuko, et al.
Publicado: (2018)

Irisin Is Target of Sphingosine-1-Phosphate/Sphingosine-1-Phosphate Receptor-Mediated Signaling in Skeletal Muscle Cells
por: Pierucci, Federica, et al.
Publicado: (2023)

Sphingosine Kinases/Sphingosine-1-Phosphate and Death Signalling in APP-Transfected Cells
por: Gassowska, Magdalena, et al.
Publicado: (2014)

Characterizing Sphingosine Kinases and Sphingosine 1-Phosphate Receptors in the Mammalian Eye and Retina
por: Porter, Hunter, et al.
Publicado: (2018)

Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System
por: Cannavo, Alessandro, et al.
Publicado: (2017)

Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
por: Ferrè, Laura, et al.
Publicado: (2023)

Sphingosine‐1‐phosphate improves outcome of no‐reflow acute myocardial infarction via sphingosine‐1‐phosphate receptor 1
por: Polzin, Amin, et al.
Publicado: (2022)

Syncope and paroxysmal atrioventricular block
por: Aste, Milena, et al.
Publicado: (2017)

To the Editor—Ablation for atrioventricular block
por: Aksu, Tolga, et al.
Publicado: (2020)

Exercise-induced Atrioventricular Block
por: Aizawa, Yoshiyasu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jr63bfat83tuq021run26u3bkr